Other ways to search: Events Calendar | UTHSC | UTHSC News



Selected Peer-Reviewed Papers (#Co-First Author; *Correspondence):

Sluter MN#,*, Li Q#, Yasmen N#, Chen Y#, Li L#, Hou R#, Yu Y, Yang C-Y, Meibohm B, and Jiang J* (2023) The Inducible Prostaglandin E Synthase in Neuroinflammatory Disorders. Experimental Biology and Medicine 248:811-819. [DOI]

Xie Y, Hou R, Hartman KL, Jiang J, Wu Z, and Li W (2023) JW-1-283 inhibits melanoma tumor growth via stabilization of the p53 pathway. Genes & Diseases (In Press) [DOI]

Qiu J, Li Q*, Li J, Zhou F, Sang P, Xia Z, Wang W, Wang L, Yu Y*, and Jiang J* (2023) Complementary roles of EP2 and EP4 receptors in malignant glioma. British Journal of Pharmacology 180:2623-2640. [DOI]

Gu M#, Yu Y#, Xue M, Jiang J*, and Cai J* (2023) The discovery of cyclic γ-AApeptides as the promising ligands targeting EP2. Bioorganic & Medicinal Chemistry Letters 87:129255. [DOI]

Sluter MN#, Bhuniya R#, Yuan X, Ramaraju A, Chen Y, Yu Y, Parmar KR, Temrikar ZH, Srivastava A, Meibohm B, Jiang J*, and Yang C-Y* (2023) Novel, Brain-Permeable, Cross-Species Benzothiazole Inhibitors of Microsomal Prostaglandin E Synthase-1 (mPGES-1) Dampen Neuroinflammation In Vitro and In Vivo. ACS Pharmacology & Translational Science 6:587-599. [DOI]

Jiang J* and Yu Y* (2023) Pharmacologically targeting transient receptor potential channels for seizures and epilepsy: Emerging preclinical evidence of druggability. Pharmacology & Therapeutics 244:108384. [DOI]

Chen Y#, Nagib MM#, Yasmen N, Sluter MN, Littlejohn TL, Yu Y, and Jiang J* (2023) Neuroinflammatory mediators in acquired epilepsy: An update. Inflammation Research 72:683-701. [DOI]

Yasmen N, Sluter MN, Li L, Yu Y, and Jiang J* (2023) Transient inhibition of microsomal prostaglandin E synthase-1 after status epilepticus blunts brain inflammation and is neuroprotective. Molecular Brain 16:14. [DOI]

Yasmen N#, Sluter MN#, Yu Y#, and Jiang J* (2023) Ganaxolone for management of seizures associated with CDKL5 deficiency disorder. Trends in Pharmacological Sciences 44:128-129. [DOI]

Jiang J*, Santhakumar V, and Zhu X (2022) Editorial: Neuroinflammation in Acquired Epilepsy. Frontiers in Cell and Developmental Biology 10:1074537. [DOI]

Hou R, Yu Y, and Jiang J* (2022) Prostaglandin E2 in neuroblastoma: Targeting synthesis or signaling? Biomedicine & Pharmacotherapy 156:113966. [DOI]

Almeida C, Pongilio RP, Móvio MI, Higa GS, Resende RR, Jiang J, Kinjo ER, and Kihar AH (2022) Distinct cell-specific roles of NOX2 and MyD88 in epileptogenesis. Frontiers in Cell and Developmental Biology 10:926776. [DOI]

Li L#, Chen Y#, Sluter MN, Hou R, Hao J, Wu Y, Chen GY, Yu Y, and Jiang J* (2022) Ablation of Siglec-E augments brain inflammation and ischemic injury. Journal of Neuroinflammation 19:191. [DOI]

Yu Y, Li W, and Jiang J* (2022) TRPC channels as emerging targets for seizure disorders. Trends in Pharmacological Sciences 43:787-798. [DOI]

Hou R, Yu Y, Sluter MN, Li L, Hao J, Fang J, Yang J, and Jiang J* (2022) Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma. Cell Reports 39:111000. [DOI]

Xu X, Zhang C, Jiang J, Xin M, and Hao J (2022) Effect of TDP43-CTFs35 on brain endothelial cell functions in cerebral ischemic injury. Molecular Neurobiology 59:4593-4611. [DOI]

Nagib MM#, Zhang S#, Yasmen N#, Li L, Hou R, Yu Y, Boda VK, Wu Z, Li W, and Jiang J* (2022) Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects. Epilepsia 63:1003-1015. [DOI]

Zhang C, Sajith AM, Xu X, Jiang J, Bowen JP, Kulkarni A, and Hao J (2022) Targeting NLRP3 Signaling by a Novel-designed Sulfonylurea Compound for Inhibition of Microglial Inflammation. Bioorganic & Medicinal Chemistry 58:116645. [DOI]

Li L, Yasmen N, Hou R, Yang S, Lee JY, Hao J, Yu Y, and Jiang J* (2022) Inducible Prostaglandin E Synthase as a Pharmacological Target for Ischemic Stroke. Neurotherapeutics 19:366-385. [DOI]

Fu H, Wang J, Wang J, Liu L, Jiang J, and Hao J (2022) 4R-cembranoid protects neuronal cells against oxygen-glucose deprivation by modulating microglial cell activation. Brain Research Bulletin 179:74-82. [DOI]

Xu X, Du L, Jiang J, Yang M, Wang Z, Wang Y, Tang T, Fu X, and Hao J (2021). Microglial TREM2 Mitigates Inflammatory Responses and Neuronal Apoptosis in Angiotensin II-Induced Hypertension in Middle-Aged Mice. Frontiers in Aging Neuroscience 13:716917. [DOI]

Sluter MN#, Hou R#, Li L#, Yasmen N, Yu Y, Liu J, and Jiang J* (2021) EP2 Antagonists (2011-2021): A Decade’s Journey from Discovery to Therapeutics. Journal of Medicinal Chemistry 64:11816-11836. [DOI]

Hou R*, Yu Y, and Jiang J* (2021) PGE2 receptors in detrusor muscle: Drugging the undruggable for urgency. Biochemical Pharmacology 184:114363. [DOI]

Jiang J* and Yu Y (2021) Small molecules targeting cyclooxygenase/prostanoid cascade in experimental brain ischemia: Do they translate? Medicinal Research Reviews 41:828-857. [DOI]

Li L, Sluter MN, Yu Y, and Jiang J* (2021) Prostaglandin E receptors as targets for ischemic stroke: Novel evidence and molecular mechanisms of efficacy. Pharmacological Research 163:105238. [DOI]

Yu Y and Jiang J* (2020) COX-2/PGE2 axis regulates hippocampal BDNF/TrkB signaling via EP2 receptor after prolonged seizures. Epilepsia Open 5:418-431. [DOI] (2021 Epilepsia Open Prize for Basic Science)

Li L, Yu Y, Hou R, Hao J, and Jiang J* (2020) Inhibiting the PGE2 Receptor EP2 Mitigates Excitotoxicity and Ischemic Injury. ACS Pharmacology & Translational Science 3:635-643. [DOI]

Yu Y, Li L, Nguyen DT, Mustafa SM, Moore BM, and Jiang J* (2020) Inverse agonism of cannabinoid receptor type 2 confers anti-inflammatory and neuroprotective effects following status epilepticus. Molecular Neurobiology 57:2830-2845. [DOI]

Nagib MM, Yu Y, and Jiang J* (2020) Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus. Pharmacology & Therapeutics 209:107504. [DOI]

Yu Y, Nguyen DT, and Jiang J* (2019) G protein-coupled receptors in acquired epilepsy: Druggability and translatability. Progress in Neurobiology 183:101682. [DOI]

Dawn A, Yao X, Yu Y, Jiang J*, and Kumari H* (2019) Assessment of the in vitro toxicity of calixarenes and a metal-seamed calixarene: a chemical pathway for clinical application. Supramolecular Chemistry 31:425-431. [DOI]

Qiu J, Li Q, Bell KA, Yao X, Du Y, Zhang E, Yu JJ, Yu Y, Shi Z*, and Jiang J* (2019) Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth. British Journal of Pharmacology 176:1680-1699. [DOI]

Jiang J*, Yu Y, Kinjo E, Du Y, Nguyen H, and Dingledine R (2019) Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury. Neuropharmacology 149:149-160. [DOI]

Jiang J*, Van TM, Ganesh T, and Dingledine R (2018) Discovery of 2-piperidinyl phenyl benzamides and trisubstituted pyrimidines as positive allosteric modulators of the prostaglandin receptor EP2. ACS Chemical Neuroscience 9:699-707. [DOI]

Hartings JA, York J, Carroll CP, Hinzman JM, Mahoney E, Krueger B, Winkler MKL, Major S, Horst V, Jahnke P, Woitzik J, Kola V, Du Y, Hagen M, Jiang J, and Dreier JP (2017) Subarachnoid blood acutely induces spreading depolarizations and early cortical infarction. Brain 140:2673-2690. [DOI]

Kang X#, Qiu J#, Li Q#, Bell KA, Du Y, Jung DW, Lee JY, Hao J, and Jiang J* (2017) Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype. Scientific Reports 7:9459. [DOI]

Jiang J*, Qiu J, Li Q, and Shi Z* (2017) Prostaglandin E2 signaling: alternative target for glioblastoma? Trends in Cancer 3:75-78. [DOI]

Qiu J, Shi Z*, and Jiang J* (2017) Cyclooxygenase-2 in glioblastoma multiforme. Drug Discovery Today 22:148-156. [DOI]

Dey A#, Kang X#, Qiu J#, Du Y, and Jiang J* (2016) Anti-inflammatory small molecules to treat seizures and epilepsy: from bench to bedside. Trends in Pharmacological Sciences 37:463-484. [DOI]

Du Y, Kemper T, Qiu J, and Jiang J* (2016) Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus. Expert Review of Neurotherapeutics 16:123-130. [DOI]

Du Y, Seibenhener ML, Yan J, Jiang J, and Wooten MC (2015) aPKC phosphorylation of HDAC6 results in increased deacetylation activity. PLOS ONE 10:e0123191. [DOI]

Fu Y, Yang M-S, Jiang J, Ganesh T, Joe E, and Dingledine R (2015) EP2 receptor signaling regulates microglia death. Molecular Pharmacology 88:161-170. [DOI]

Jiang J*, Yang M-S, Quan Y, Gueorguieva P, Ganesh T, and Dingledine R (2015) Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Neurobiology of Disease 76:126-135. [DOI]

Varvel NH*, Jiang J*, and Dingledine R* (2015) Candidate drug targets for prevention or modification of epilepsy. Annual Review of Pharmacology and Toxicology 55:229-247. [DOI]

Ganesh T, Jiang J, and Dingledine R (2014) Development of second generation EP2 antagonists with high selectivity. European Journal of Medicinal Chemistry 82:521-535. [DOI]

Ganesh T, Jiang J, Yang M, and Dingledine R (2014) Lead optimization studies of cinnamic amide EP2 antagonists. Journal of Medicinal Chemistry 57:4173-4184. [DOI]

Rojas A, Jiang J, Ganesh T, Yang M, Lelutiu N, Gueorguieva P, and Dingledine R (2014) Cyclooxygenase-2 in epilepsy. Epilepsia 55:17-25. [DOI]

Yan J, Seibenhener ML, Calderill-Barbosa L, Diaz-Meco MT, Moscat J, Jiang J, Wooten MW, and Wooten MC (2013) SQSTM1/p62 interacts with HDAC6 and regulates deacetylase activity. PLOS ONE 8:e76016. [DOI]

Ganesh T#,*, Jiang J#,*, Shashidharamurthy R, and Dingledine R (2013) Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists. ACS Medicinal Chemistry Letters 4:616-621. [DOI]

Jiang J* and Dingledine R* (2013) Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends in Pharmacological Sciences 34:413-423. [DOI]

Seibenhener ML, Zhao T, Du Y, Calderill-Barbosa L, Yan J, Jiang J, Wooten MW, and Wooten MC (2013) Behavioral effects of SQSTM1/p62 overexpression in mice: Support for a mitochondrial role in depression and anxiety. Behavioural Brain Research 248:94-103. [DOI]

Quan Y, Jiang J, and Dingledine R (2013) EP2 receptor signaling pathways regulate classical activation of microglia. Journal of Biological Chemistry 288:9293-9302. [DOI]

Jiang J*, Quan Y, Ganesh T, Pouliot WA, Dudek FE, and Dingledine R (2013) Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proceedings of the National Academy of Sciences of the USA 110:3591-3596. [DOI]

Jiang J* and Dingledine R (2013) Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. Journal of Pharmacology and Experimental Therapeutics 344:360-367. [DOI]

Jiang J#,*, Ganesh T#, Du Y#, Quan Y, Serrano G, Qui M, Speigel I, Rojas A, Lelutiu N, and Dingledine R* (2012) Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proceedings of the National Academy of Sciences of the USA 109:3149-3154. [DOI]

Jiang J#, Ganesh T#, Du Y#, Thepchatri P, Rojas A, Lewis I, Kurtkaya S, Li L, Qui M, Serrano G, Shaw R, Sun A, and Dingledine R (2010) Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proceedings of the National Academy of Sciences of the USA 107:2307-2312. [DOI]

Jiang J, Parameshwaran K, Seibenhener ML, Kang MG, Suppiramaniam V, Huganir RL, Diaz-Meco MT, and Wooten MW (2009) AMPA receptor trafficking and synaptic plasticity require SQSTM1/p62. Hippocampus 19:392-406. [DOI]

Jadhav T, Geetha T, Jiang J, and Wooten MW (2008) Identification of a conserved consensus site for TRAF6/p62 substrate polyubiquitination. Biochemical and Biophysical Research Communications 371:521-524. [DOI]

Jiang J, Suppiramaniam V, and Wooten MW (2006-2007) Posttranslational modifications and receptor-associated proteins in AMPA receptor trafficking and synaptic plasticity. NeuroSignals 15:266-282. [DOI]

Geetha T, Jiang J, and Wooten MW (2005) Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling. Molecular Cell 20:301-312. [DOI]